The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography

Anesthesia and Analgesia

Volumn 103, Issue 4, 2006, Pages 841-845

  Audu, Paul ^a   Nielsen, Vance G ^b   Armstead, Valerie ^a   Powell, Garry ^a   Kim, Jerry ^a   Kim, Larry ^a   Mehta, Munira ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; HEPARIN; INFUSORIAL EARTH; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; COMPLEX FORMATION; ENDOTHELIUM; HEMOSTASIS; HUMAN; IN VITRO STUDY; KINETICS; MONITORING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; DIATOMACEOUS EARTH; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VII DEFICIENCY; HUMANS; LIPOPROTEINS; THROMBELASTOGRAPHY; THROMBOPLASTIN;

EID: 33750058284     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000237285.40106.1e     Document Type: Article

References (12)

1. Panteleev MA, Zarnitsina VI, Ataullakhanov FI. Tissue factor pathway inhibitor: a possible mechanism of action. Eur J Biochem 2002;269:2016-31.
2. Hoppensteadt DA, Fasanella A, Fareed J. Effect of protamine on heparin releasable TFPI antigen levels in normal volunteers. Thromb Res 1995;79:325-30.
3. Vila V, Martinez-Sales V, Reganon E, et al. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes. Haematologica 2001;86:729-34.
4. Adams MJ, Cardigan RA, Marchant WA, et al. Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2002;16:59-63.
5. Brodin E, Svensson B, Paulssen RH, et al. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. J Lab Clin Med 2004;144:246-53.
6. Ertenli I, Kiraz S, Celik I, et al. Changes in the concentration and distribution of tissue factor pathway in Behcet's disease and systemic lupus erythematosis: effect on the prothrombotic state. Ann Rheum Dis 2001;60:1149-51.
7. Hakki SI, Fareed J, Hoppensteadt DA, et al. Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. Clin Appl Thromb Hemost 2000;6:206-12.
8. Egli GA, Zollinger A, Seifert B, et al. Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation. Br J Anaesth 1997;78:684-9.
9. Gorton H, Lyons G, Manraj P. Preparation for regional anaesthesia induces changes in thrombelastography. Br J Anaesth 2000;84:403-4.
10. Ng KFJ, Lam CCK, Chan LC. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. Br J Anaesth 2002;88:475-80.
11. Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via Thrombelastography®: critical roles of fibrinogen and Factors II, VII, X and XII. Acta Anaesthesiol Scand 2005;49:222-31.
12. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006;17:75-81.